Dr. Colleen Jonsson, University of Tennessee Health Science Center (IMAGE)
Caption
Based on virtual and in vitro antiviral screening that began in the earlier months of the COVID-19 pandemic, the researchers led at UTHSC by Colleen Jonsson, PhD, identified zuclopenthixol, nebivolol, and amodiaquine as promising therapeutics for the virus in its early stages.
Credit
UTHSC
Usage Restrictions
None
License
Licensed content